Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Simic, B; Hermann, M; Shaw, S G; Bigler, L; Stalder, U; Dörries, C; Besler, C; Lüscher, T F; Ruschitzka, F (2012). Torcetrapib impairs endothelial function in hypertension. European Heart Journal, 33(13):1615-1624.

Besler, C; Heinrich, K; Rohrer, L; Doerries, C; Riwanto, M; Shih, D M; Chroni, A; Yonekawa, K; Stein, S; Schaefer, N; Mueller, M; Akhmedov, A; Daniil, G; Manes, C; Templin, C; Wyss, C; Maier, W; Tanner, F C; Matter, C M; Corti, R; Furlong, C; Lusis, A J; von Eckardstein, Arnold; Fogelman, A M; Lüscher, T F; Landmesser, U (2011). Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation, 121(7):2693-708.

Sorrentino, S A; Doerries, C; Manes, C; Speer, T; Dessy, C; Lobysheva, I; Mohmand, W; Akbar, R; Bahlmann, F; Besler, C; Schaefer, A; Hilfiker-Kleiner, D; Lüscher, T F; Balligand, J L; Drexler, H; Landmesser, U (2011). Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. Journal of the American College of Cardiology, 57(5):601-611.

Sorrentino, S A; Besler, C; Rohrer, L; Meyer, Martin; Heinrich, K; Bahlmann, F H; Mueller, M; Horváth, T; Doerries, C; Heinemann, M; Flemmer, S; Markowski, A; Manes, C; Bahr, M J; Haller, H; von Eckardstein, Arnold; Drexler, H; Landmesser, U (2010). Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 121(1):110-122.

Besler, C; Heinrich, K; Riwanto, M; Lüscher, T F; Landmesser, U (2010). High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Current Pharmaceutical Design, 16(13):1480-1493.

Stein, S; Lohmann, C; Schäfer, N; Hofmann, J; Rohrer, L; Besler, C; Rothgiesser, K M; Becher, B; Hottiger, M O; Borén, J; McBurney, M W; Landmesser, U; Lüscher, T F; Matter, C M (2010). SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. European Heart Journal, 31(18):2301-2309.

Stein, S; Schäfer, N; Breitenstein, A; Besler, C; Winnik, S; Lohmann, C; Heinrich, K; Brokopp, C E; Handschin, C; Landmesser, U; Tanner, F C; Lüscher, T F; Matter, C M (2010). SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging, 2(6):353-360.

Charakida, M; Besler, C; Batuca, J R; Sangle, S; Marques, S; Sousa, M; Wang, G; Tousoulis, D; Delgado Alves, J; Loukogeorgakis, S P; Mackworth-Young, C; D'Cruz, D; Lüscher, Thomas F; Landmesser, U; Deanfield, J E (2009). Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA: The Journal of the American Medical Association, 302(11):1210-1217.

Osto, E; Kuroedov, A; Mocharla, P; Akhmedov, A; Besler, C; Rohrer, L; von Eckardstein, A; Iliceto, S; Volpe, M; Lüscher, T F; Cosentino, F (2008). Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation, 118(21):2174-2182.

Besler, C; Doerries, C; Giannotti, G; Luescher, T F; Landmesser, U (2008). Pharmacological approaches to improve endothelial repair mechanisms. Expert Review of Cardiovascular Therapy, 6(8):1071-1082.

This list was generated on Wed Jun 26 15:06:11 2019 CEST.